Rising Demand for Pyelonephritis Drug Market Key Players, Growth Analysis during 2022-2028

The global pyelonephritis drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). A kidney infection, commonly known as pyelonephritis, is a form of urinary tract infection characterized by inflammation of one or both kidneys. Bacteria or a virus causes the illness, which usually starts in the urinary bladder and spreads to one or both kidneys. Confusion and back pain, chills and high fever, nausea and vomiting, back, side, and groyne discomfort, and painful urination are all signs or symptoms of pyelonephritis, which might vary based on age. Kidney stones, a weaker immune system, anatomical abnormalities with the urinary tract, urine reflux issues, and nerve damage surrounding the bladder are all some factors that cause pyelonephritis. Owing to the high prevalence and incidence rates of pyelonephritis problems around the world, the global pyelonephritis treatment market is expected to rise rapidly during the forecast period. Each year, over 200,000 hospitalizations for acute pyelonephritis are reported in the US. As a result, the global pyelonephritis treatment market is likely to be driven by a huge population base with a kidney infection during the forecast period.

To Request a Sample of our Report on Pyelonephritis Drug Market: https://www.omrglobal.com/request-sample/pyelonephritis-drug-market

The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, in October 2021, Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases, announced that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for approval of tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis, caused by susceptible microorganisms.

Market Coverage

· The market number available for - 2021-2028

· Base year- 2021

· Forecast period- 2022-2028

Segment Covered-

· By Product Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Merck & Co, Inc., and AstraZeneca plc, among others.

(Get 15% Discount on Buying this Report)

A full Report of Pyelonephritis Drug Market is Available @ https://www.omrglobal.com/industry-reports/pyelonephritis-drug-market

Global Pyelonephritis Drug Market Report by Segment

By Product Type

· Finafloxacin

· Fosfomycin Tromethamine

· Nacubactam

· Plazomicin Sulfate

· Others

By Application

· Hospital

· Clinic

· Others

Global Pyelonephritis Drug Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.